The executive director of the organization says gender inequality is one of the most important drivers of new infections, ...

GILD and partner MRK advance novel investigational combination regimen, a weekly oral HIV treatment, to phase III.

Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

PASIGHAT, 17 Oct: “One should not lose sight of the goal to eliminate HIV/AIDS; it is time to create awareness among the people and break the chain of infection,” said Pasighat East MLA Tapi Darang ...

In June, we heard what could be this year’s biggest HIV breakthrough: a twice-yearly injection can prevent HIV infection. A ...

Responding to growing pressure, ViiV Healthcare announced steps to widen access to its HIV prevention medicine in low- and ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced additional data from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752) ...

How Was It Studied for the Prevention of HIV? Two large studies were conducted to see if Apretude is safe and effective as a PrEP regimen in people at risk of getting HIV. In both studies ...

Although the initiative represents a resource for the global population, the Decade also provides a unique opportunity for the large community of people living with HIV in terms of increased ... to ...

Thanks to advancements in prevention and treatment, global HIV infection rates have dramatically declined in recent years. But HIV still affects over 38 million people around the world.